Search
Acylcarnitine (12Z)-10-Hydroxyoctadecenoylcarnitine
smpdb.ca/view/SMP0124327Metabolic(12Z)-10-Hydroxyoctadecenoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (12Z)-10-hydroxyoctadecenoyl-CoA reacts with L-carnitine to form (12Z)-10-hydroxyoctadecenoylcarnitine.
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreCardiolipin Biosynthesis CL(10:0/10:0/18:2(9Z,11Z)/a-21:0)
smpdb.ca/view/SMP0175523MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(10:0/10:0/18:2(9Z,11Z)/i-20:0)
smpdb.ca/view/SMP0175526MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(10:0/10:0/18:2(9Z,11Z)/i-21:0)
smpdb.ca/view/SMP0175527MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(10:0/10:0/18:2(9Z,11Z)/i-24:0)
smpdb.ca/view/SMP0175529MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(10:0/10:0/a-15:0/18:2(9Z,11Z))
smpdb.ca/view/SMP0175616MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(10:0/10:0/a-17:0/18:2(9Z,11Z))
smpdb.ca/view/SMP0175638MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.
Products: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.Disopyramide
go.drugbank.com/drugs/DB00280ApprovedInvestigationalA class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also po...
Categories: Heterocyclic Compounds, 1-RingProducts: NORPACE 100 MG KAPSÜL, 100 ADET, NORPACE 100 MG KAPSÜL, 50 ADET4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase
go.drugbank.com/bio_entities/BE0004121TargetMycobacterium tuberculosisCatalyzes the hydrolysis of a carbon-carbon bond in 4,5: 9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate (4,9-DSHA) to yield 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate (DOHNAA) and
Polypeptides: 4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase